Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Peptide-based Robust and Innovative Molecular Condensate Engineering for Antibody-Drug Conjugates

Project description

A new way to build targeted cancer drugs

Antibody drug conjugates are a promising class of cancer therapies. They combine antibodies that recognise tumour cells with powerful drugs that destroy them. Producing these complex medicines, however, remains difficult, and most candidates fail in early development because current chemical methods create unstable and inconsistent products. The ERC-funded PRIME-ADC project is designing tiny peptide-based ‘microreactors’ that help attach drugs to antibodies with high precision. These condensates bring the necessary components together while separating unwanted chemical residues, making the process more efficient and easier to purify. The production of more stable and predictable antibody drug conjugates will improve the development of targeted cancer therapies and support the next generation of biotech innovation.

Objective

Antibody drug conjugates are among the most promising targeted cancer therapies, combining the specificity of monoclonal antibodies with the potency of cytotoxic drugs. Yet, more than 80% of ADC candidates fail to progress beyond early clinical stages. A key reason lies in current conjugation chemistries: lysine- and cysteine-based methods yield heterogeneous products with unstable linkages, poor pharmacokinetics, and high manufacturing inefficiencies, wasting up to 50% of material. Copper-catalyzed click chemistry (CuAAC) offers the promise of precise, site-specific conjugation, but copper toxicity has prevented its industrial use, while copper-free alternatives require costly antibody engineering and compromise reaction kinetics.
PRIME-ADC introduces a breakthrough solution: peptide-based biomolecular condensates engineered as programmable microreactors for CuAAC conjugation. These condensates selectively recruit antibodies and hydrophobic drugs into their dense phase, enabling efficient, stoichiometric coupling with controlled drug-to-antibody ratios. At the same time, copper ions remain in the dilute phase and are removed via simple centrifugation, eliminating toxicity risks and simplifying downstream purification. This one-pot, aqueous, and recyclable system yields homogeneous, stable ADCs with predictable pharmacokinetics, while reducing solvent use, energy demand, and purification costs.
The proof of concept will validate PRIME-ADC with cetuximab and clinically relevant payloads, benchmark performance against standard chemistries, and demonstrate regulatory-compliant copper clearance. In parallel, business feasibility will be established through market validation, competitive benchmarking, and the design of a spin-out company. If successful, PRIME-ADC will unlock the clinical and commercial potential of next-generation ADCs, reduce environmental burden, and lay the foundation for a high-growth European biotech venture.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-POC

See all projects funded under this call

Host institution

TEL AVIV UNIVERSITY
Net EU contribution
€ 123 000,00
Total cost
No data

Beneficiaries (2)